25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

NanoRepro AG
Buy, Hold or Sell?

Let's analyze Nanorepro together

I guess you are interested in NanoRepro AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of NanoRepro AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about NanoRepro AG

I send you an email if I find something interesting about NanoRepro AG.

1. Quick Overview

1.1. Quick analysis of Nanorepro (30 sec.)










1.2. What can you expect buying and holding a share of Nanorepro? (30 sec.)

How much money do you get?

How much money do you get?
€0.66
When do you have the money?
1 year
How often do you get paid?
20.0%

What is your share worth?

Current worth
€3.13
Expected worth in 1 year
€0.94
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
€-1.59
Return On Investment
-85.2%

For what price can you sell your share?

Current Price per Share
€1.87
Expected price per share
€1.6 - €2.19
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Nanorepro (5 min.)




Live pricePrice per Share (EOD)
€1.87
Intrinsic Value Per Share
€-8.59 - €-1.58
Total Value Per Share
€-5.47 - €1.55

2.2. Growth of Nanorepro (5 min.)




Is Nanorepro growing?

Current yearPrevious yearGrowGrow %
How rich?$44.7m$52.5m-$7.8m-17.5%

How much money is Nanorepro making?

Current yearPrevious yearGrowGrow %
Making money-$5.1m-$4.1m-$1m-20.5%
Net Profit Margin-144.3%-9.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Nanorepro (5 min.)




2.4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  


Richest
#82 / 140

Most Revenue
#107 / 140

Most Profit
#97 / 140

Most Efficient
#112 / 140
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Nanorepro?

Welcome investor! Nanorepro's management wants to use your money to grow the business. In return you get a share of Nanorepro.

First you should know what it really means to hold a share of Nanorepro. And how you can make/lose money.

Speculation

The Price per Share of Nanorepro is €1.865. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nanorepro.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nanorepro, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €3.13. Based on the TTM, the Book Value Change Per Share is €-0.55 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.79 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.15 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nanorepro.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.40-21.6%-0.40-21.6%-0.32-17.1%0.3720.1%0.168.8%
Usd Book Value Change Per Share-0.61-32.5%-0.61-32.5%-0.87-46.8%0.6031.9%0.3317.8%
Usd Dividend Per Share0.178.9%0.178.9%0.5529.7%0.147.7%0.073.9%
Usd Total Gains Per Share-0.44-23.6%-0.44-23.6%-0.32-17.1%0.7439.6%0.4021.7%
Usd Price Per Share2.21-2.21-2.44-3.58-2.38-
Price to Earnings Ratio-5.49--5.49--7.64-2.16--57.23-
Price-to-Total Gains Ratio-5.02--5.02--7.64--0.97-12.46-
Price to Book Ratio0.64-0.64-0.60-2.18-3.42-
Price-to-Total Gains Ratio-5.02--5.02--7.64--0.97-12.46-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.0662335
Number of shares483
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.170.14
Usd Book Value Change Per Share-0.610.60
Usd Total Gains Per Share-0.440.74
Gains per Quarter (483 shares)-212.49357.13
Gains per Year (483 shares)-849.941,428.53
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1321-1171-86027811501419
2641-2341-171055623012848
3962-3512-256083534514277
41283-4683-3410111346015706
51604-5853-4260139157527135
61924-7024-5110166969028564
72245-8195-5960194780529993
82566-9365-68102226920311422
92887-10536-766025041035312851
103207-11707-851027821150314280

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%2.08.00.020.0%2.09.00.018.2%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%7.03.00.070.0%8.03.00.072.7%
Dividend per Share1.00.00.0100.0%2.00.01.066.7%2.00.03.040.0%2.00.08.020.0%2.00.09.018.2%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%7.03.00.070.0%8.03.00.072.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of NanoRepro AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.547-0.5470%-0.789+44%0.537-202%0.300-282%
Book Value Per Share--3.1293.1290%3.676-15%2.449+28%1.356+131%
Current Ratio--52.59052.5900%42.026+25%22.401+135%15.915+230%
Debt To Asset Ratio--0.0260.0260%0.041-37%0.140-81%0.115-77%
Debt To Equity Ratio--0.0270.0270%0.043-38%0.185-86%0.143-81%
Dividend Per Share--0.1500.1500%0.500-70%0.130+15%0.065+131%
Eps---0.363-0.3630%-0.289-21%0.338-207%0.147-346%
Free Cash Flow Per Share---0.795-0.7950%0.762-204%0.093-959%0.016-5131%
Free Cash Flow To Equity Per Share---0.979-0.9790%0.251-490%0.276-455%0.159-715%
Gross Profit Margin--1.6691.6690%1.000+67%1.134+47%1.067+56%
Intrinsic Value_10Y_max---1.583--------
Intrinsic Value_10Y_min---8.595--------
Intrinsic Value_1Y_max--0.123--------
Intrinsic Value_1Y_min---0.207--------
Intrinsic Value_3Y_max--0.155--------
Intrinsic Value_3Y_min---1.193--------
Intrinsic Value_5Y_max---0.072--------
Intrinsic Value_5Y_min---2.796--------
Market Cap23710118.000-9%25743027.13525743027.1350%28452819.465-10%41521908.874-38%27571542.809-7%
Net Profit Margin---1.443-1.4430%-0.097-93%-0.447-69%-0.497-66%
Operating Margin---1.166-1.1660%-0.118-90%-0.370-68%-0.489-58%
Operating Ratio--2.3682.3680%1.118+112%1.410+68%1.509+57%
Pb Ratio0.596-7%0.6380.6380%0.600+6%2.184-71%3.418-81%
Pe Ratio-5.136+7%-5.494-5.4940%-7.640+39%2.156-355%-57.228+942%
Price Per Share1.865-7%1.9951.9950%2.205-10%3.231-38%2.151-7%
Price To Free Cash Flow Ratio-2.345+7%-2.508-2.5080%2.892-187%-8.993+259%-15.559+520%
Price To Total Gains Ratio-4.697+7%-5.024-5.0240%-7.640+52%-0.966-81%12.459-140%
Quick Ratio--46.42246.4220%36.449+27%19.115+143%12.357+276%
Return On Assets---0.113-0.1130%-0.075-33%0.018-717%-0.078-31%
Return On Equity---0.116-0.1160%-0.079-32%0.053-319%-0.069-40%
Total Gains Per Share---0.397-0.3970%-0.289-27%0.667-159%0.365-209%
Usd Book Value--44732428.58944732428.5890%52551406.249-15%34973763.317+28%19332366.416+131%
Usd Book Value Change Per Share---0.606-0.6060%-0.874+44%0.595-202%0.332-282%
Usd Book Value Per Share--3.4673.4670%4.073-15%2.714+28%1.502+131%
Usd Dividend Per Share--0.1660.1660%0.554-70%0.144+15%0.072+131%
Usd Eps---0.402-0.4020%-0.320-21%0.375-207%0.163-346%
Usd Free Cash Flow---11371042.440-11371042.4400%10900406.520-204%1329479.778-955%235318.182-4932%
Usd Free Cash Flow Per Share---0.881-0.8810%0.845-204%0.103-959%0.018-5131%
Usd Free Cash Flow To Equity Per Share---1.085-1.0850%0.278-490%0.305-455%0.177-715%
Usd Market Cap26268439.732-9%28520699.76328520699.7630%31522878.685-10%46002122.842-38%30546512.278-7%
Usd Price Per Share2.066-7%2.2102.2100%2.443-10%3.580-38%2.383-7%
Usd Profit---5190844.923-5190844.9230%-4126082.172-21%4834923.251-207%2109662.299-346%
Usd Revenue--3596989.0173596989.0170%42641117.772-92%49324982.971-93%25573787.540-86%
Usd Total Gains Per Share---0.440-0.4400%-0.320-27%0.739-159%0.404-209%
 EOD+3 -5MRQTTM+0 -0YOY+10 -265Y+13 -2310Y+12 -24

3.3 Fundamental Score

Let's check the fundamental score of NanoRepro AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.136
Price to Book Ratio (EOD)Between0-10.596
Net Profit Margin (MRQ)Greater than0-1.443
Operating Margin (MRQ)Greater than0-1.166
Quick Ratio (MRQ)Greater than146.422
Current Ratio (MRQ)Greater than152.590
Debt to Asset Ratio (MRQ)Less than10.026
Debt to Equity Ratio (MRQ)Less than10.027
Return on Equity (MRQ)Greater than0.15-0.116
Return on Assets (MRQ)Greater than0.05-0.113
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of NanoRepro AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.709
Ma 20Greater thanMa 501.862
Ma 50Greater thanMa 1001.824
Ma 100Greater thanMa 2001.779
OpenGreater thanClose1.785
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About NanoRepro AG

NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, such as family planning, and preventive healthcare line products; tests for hospitals and medical practices to detect aids, Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women, including Alphabiol Beauty Elixier for the skin shine based on combination of micronutrients; Alphabiol Fertility for men; Alphabiol Curcumin Elixier mit Curcumin + Vitamin D, an essential nutrient for Vitamin D through online shops and pharmacies. The company was founded in 2006 and is headquartered in Marburg, Germany.

Fundamental data was last updated by Penke on 2024-09-02 15:45:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Nanorepro earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Nanorepro to the Diagnostics & Research industry mean.
  • A Net Profit Margin of -144.3% means that €-1.44 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of NanoRepro AG:

  • The MRQ is -144.3%. The company is making a huge loss. -2
  • The TTM is -144.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-144.3%TTM-144.3%0.0%
TTM-144.3%YOY-9.7%-134.6%
TTM-144.3%5Y-44.7%-99.7%
5Y-44.7%10Y-49.7%+5.0%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-144.3%-2.7%-141.6%
TTM-144.3%-9.4%-134.9%
YOY-9.7%-5.1%-4.6%
5Y-44.7%-3.2%-41.5%
10Y-49.7%-0.3%-49.4%
4.3.1.2. Return on Assets

Shows how efficient Nanorepro is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nanorepro to the Diagnostics & Research industry mean.
  • -11.3% Return on Assets means that Nanorepro generated €-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of NanoRepro AG:

  • The MRQ is -11.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.3%TTM-11.3%0.0%
TTM-11.3%YOY-7.5%-3.8%
TTM-11.3%5Y1.8%-13.1%
5Y1.8%10Y-7.8%+9.7%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.3%-1.2%-10.1%
TTM-11.3%-1.8%-9.5%
YOY-7.5%-0.9%-6.6%
5Y1.8%-0.6%+2.4%
10Y-7.8%-0.5%-7.3%
4.3.1.3. Return on Equity

Shows how efficient Nanorepro is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nanorepro to the Diagnostics & Research industry mean.
  • -11.6% Return on Equity means Nanorepro generated €-0.12 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of NanoRepro AG:

  • The MRQ is -11.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.6%TTM-11.6%0.0%
TTM-11.6%YOY-7.9%-3.8%
TTM-11.6%5Y5.3%-16.9%
5Y5.3%10Y-6.9%+12.2%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.6%-0.5%-11.1%
TTM-11.6%-1.6%-10.0%
YOY-7.9%-0.1%-7.8%
5Y5.3%-1.2%+6.5%
10Y-6.9%-1.6%-5.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of NanoRepro AG.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Nanorepro is operating .

  • Measures how much profit Nanorepro makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nanorepro to the Diagnostics & Research industry mean.
  • An Operating Margin of -116.6% means the company generated €-1.17  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of NanoRepro AG:

  • The MRQ is -116.6%. The company is operating very inefficient. -2
  • The TTM is -116.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-116.6%TTM-116.6%0.0%
TTM-116.6%YOY-11.8%-104.8%
TTM-116.6%5Y-37.0%-79.6%
5Y-37.0%10Y-48.9%+11.9%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-116.6%-10.1%-106.5%
TTM-116.6%-8.7%-107.9%
YOY-11.8%1.1%-12.9%
5Y-37.0%-0.4%-36.6%
10Y-48.9%3.2%-52.1%
4.3.2.2. Operating Ratio

Measures how efficient Nanorepro is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 2.37 means that the operating costs are €2.37 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of NanoRepro AG:

  • The MRQ is 2.368. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.368. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.368TTM2.3680.000
TTM2.368YOY1.118+1.250
TTM2.3685Y1.410+0.958
5Y1.41010Y1.509-0.099
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3681.365+1.003
TTM2.3681.323+1.045
YOY1.1181.301-0.183
5Y1.4101.265+0.145
10Y1.5091.196+0.313
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of NanoRepro AG.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Nanorepro is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 52.59 means the company has €52.59 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of NanoRepro AG:

  • The MRQ is 52.590. The company is very able to pay all its short-term debts. +2
  • The TTM is 52.590. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ52.590TTM52.5900.000
TTM52.590YOY42.026+10.564
TTM52.5905Y22.401+30.189
5Y22.40110Y15.915+6.485
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ52.5902.055+50.535
TTM52.5902.112+50.478
YOY42.0262.492+39.534
5Y22.4012.718+19.683
10Y15.9153.264+12.651
4.4.3.2. Quick Ratio

Measures if Nanorepro is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nanorepro to the Diagnostics & Research industry mean.
  • A Quick Ratio of 46.42 means the company can pay off €46.42 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of NanoRepro AG:

  • The MRQ is 46.422. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 46.422. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ46.422TTM46.4220.000
TTM46.422YOY36.449+9.973
TTM46.4225Y19.115+27.307
5Y19.11510Y12.357+6.759
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ46.4221.107+45.315
TTM46.4221.230+45.192
YOY36.4491.685+34.764
5Y19.1152.025+17.090
10Y12.3572.360+9.997
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of NanoRepro AG.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Nanorepro assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nanorepro to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 0.03 means that Nanorepro assets are financed with 2.6% credit (debt) and the remaining percentage (100% - 2.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of NanoRepro AG:

  • The MRQ is 0.026. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.026. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.026TTM0.0260.000
TTM0.026YOY0.041-0.015
TTM0.0265Y0.140-0.114
5Y0.14010Y0.115+0.025
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0260.443-0.417
TTM0.0260.439-0.413
YOY0.0410.360-0.319
5Y0.1400.424-0.284
10Y0.1150.447-0.332
4.5.4.2. Debt to Equity Ratio

Measures if Nanorepro is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nanorepro to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 2.7% means that company has €0.03 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of NanoRepro AG:

  • The MRQ is 0.027. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.027. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.027TTM0.0270.000
TTM0.027YOY0.043-0.016
TTM0.0275Y0.185-0.158
5Y0.18510Y0.143+0.043
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0270.640-0.613
TTM0.0270.669-0.642
YOY0.0430.487-0.444
5Y0.1850.669-0.484
10Y0.1430.721-0.578
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Nanorepro generates.

  • Above 15 is considered overpriced but always compare Nanorepro to the Diagnostics & Research industry mean.
  • A PE ratio of -5.49 means the investor is paying €-5.49 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of NanoRepro AG:

  • The EOD is -5.136. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.494. Based on the earnings, the company is expensive. -2
  • The TTM is -5.494. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.136MRQ-5.494+0.358
MRQ-5.494TTM-5.4940.000
TTM-5.494YOY-7.640+2.145
TTM-5.4945Y2.156-7.650
5Y2.15610Y-57.228+59.384
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-5.136-0.433-4.703
MRQ-5.494-0.907-4.587
TTM-5.494-0.791-4.703
YOY-7.640-0.088-7.552
5Y2.1560.568+1.588
10Y-57.2282.553-59.781
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of NanoRepro AG:

  • The EOD is -2.345. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.508. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.508. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.345MRQ-2.508+0.163
MRQ-2.508TTM-2.5080.000
TTM-2.508YOY2.892-5.400
TTM-2.5085Y-8.993+6.484
5Y-8.99310Y-15.559+6.567
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-2.345-0.581-1.764
MRQ-2.508-1.060-1.448
TTM-2.508-1.281-1.227
YOY2.892-3.128+6.020
5Y-8.993-1.518-7.475
10Y-15.559-2.468-13.091
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Nanorepro is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 0.64 means the investor is paying €0.64 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of NanoRepro AG:

  • The EOD is 0.596. Based on the equity, the company is cheap. +2
  • The MRQ is 0.638. Based on the equity, the company is cheap. +2
  • The TTM is 0.638. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.596MRQ0.638-0.042
MRQ0.638TTM0.6380.000
TTM0.638YOY0.600+0.038
TTM0.6385Y2.184-1.547
5Y2.18410Y3.418-1.234
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD0.5961.880-1.284
MRQ0.6382.071-1.433
TTM0.6382.167-1.529
YOY0.6002.338-1.738
5Y2.1843.795-1.611
10Y3.4184.111-0.693
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets41,458
Total Liabilities1,082
Total Stockholder Equity40,376
 As reported
Total Liabilities 1,082
Total Stockholder Equity+ 40,376
Total Assets = 41,458

Assets

Total Assets41,458
Total Current Assets35,414
Long-term Assets6,044
Total Current Assets
Cash And Cash Equivalents 16,596
Short-term Investments 4,025
Net Receivables 6,615
Inventory 604
Other Current Assets 7,574
Total Current Assets  (as reported)35,414
Total Current Assets  (calculated)35,414
+/-0
Long-term Assets
Property Plant Equipment 0
Intangible Assets 3,335
Long-term Assets Other 4,025
Long-term Assets  (as reported)6,044
Long-term Assets  (calculated)7,359
+/- 1,316

Liabilities & Shareholders' Equity

Total Current Liabilities673
Long-term Liabilities409
Total Stockholder Equity40,376
Total Current Liabilities
Accounts payable 170
Other Current Liabilities 503
Total Current Liabilities  (as reported)673
Total Current Liabilities  (calculated)673
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)409
Long-term Liabilities  (calculated)0
+/- 409
Total Stockholder Equity
Common Stock12,904
Retained Earnings 5,216
Accumulated Other Comprehensive Income 22,446
Other Stockholders Equity -191
Total Stockholder Equity (as reported)40,376
Total Stockholder Equity (calculated)40,376
+/-0
Other
Capital Stock12,904
Cash and Short Term Investments 20,621
Common Stock Shares Outstanding 12,904
Liabilities and Stockholders Equity 41,458
Net Debt -16,596
Net Invested Capital 40,376
Net Working Capital 34,741
Property Plant and Equipment Gross 154



6.2. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-31
> Total Assets 
434
450
1,942
998
1,061
1,785
2,172
2,439
3,513
4,197
5,806
4,803
11,170
79,149
49,475
41,458
41,45849,47579,14911,1704,8035,8064,1973,5132,4392,1721,7851,0619981,942450434
   > Total Current Assets 
287
319
1,774
736
785
997
725
794
1,045
1,656
3,133
1,819
11,072
78,999
46,030
35,414
35,41446,03078,99911,0721,8193,1331,6561,0457947259977857361,774319287
       Cash And Cash Equivalents 
171
192
912
229
59
503
120
231
530
528
1,770
737
1,164
28,018
31,260
16,596
16,59631,26028,0181,1647371,77052853023112050359229912192171
       Short-term Investments 
0
2
2
2
0
0
0
0
0
0
0
0
0
0
0
4,025
4,025000000000002220
       Net Receivables 
0
0
525
163
328
182
39
36
31
332
603
443
7,310
32,448
8,661
6,615
6,6158,66132,4487,31044360333231363918232816352500
       Inventory 
68
63
203
282
351
241
440
403
423
735
678
569
2,566
17,948
1,622
604
6041,62217,9482,5665696787354234034402413512822036368
       Other Current Assets 
47
62
132
60
46
71
126
125
61
61
82
69
32
585
4,487
7,574
7,5744,48758532698261611251267146601326247
   > Long-term Assets 
148
131
168
263
276
788
1,443
1,641
1,813
1,971
2,073
2,985
98
150
3,446
6,044
6,0443,446150982,9852,0731,9711,8131,6411,443788276263168131148
       Property Plant Equipment 
63
53
66
70
54
38
29
21
13
11
6
3
1
1
0
0
00113611132129385470665363
       Long Term Investments 
0
0
0
0
0
0
0
25
25
25
25
0
0
0
0
0
00000252525250000000
       Intangible Assets 
0
0
57
0
223
749
1,414
1,596
1,775
1,935
2,042
2,351
66
58
3,355
3,335
3,3353,35558662,3512,0421,9351,7751,5961,41474922305700
       Long-term Assets Other 
45
2
2
2
0
0
-1,443
-1,641
-557
-557
-598
8
6
66
65
4,025
4,025656668-598-557-557-1,641-1,4430022245
> Total Liabilities 
196
246
374
140
198
141
265
165
479
373
188
374
3,180
21,540
2,042
1,082
1,0822,04221,5403,180374188373479165265141198140374246196
   > Total Current Liabilities 
192
241
286
134
158
115
187
93
348
291
120
351
2,200
11,006
1,095
673
6731,09511,0062,20035112029134893187115158134286241192
       Short-term Debt 
188
202
2
54
40
28
121
13
150
130
0
198
1,202
150
0
0
001501,2021980130150131212840542202188
       Short Long Term Debt 
0
0
0
0
0
28
121
13
156
136
0
198
1,202
150
0
0
001501,2021980136156131212800000
       Accounts payable 
0
37
39
45
88
68
54
74
167
82
95
128
359
1,993
371
170
1703711,9933591289582167745468884539370
       Other Current Liabilities 
4
3
246
12
25
14
12
6
18
69
26
14
639
4,966
707
503
5037074,9666391426691861214251224634
   > Long-term Liabilities 
4
5
88
6
41
25
78
13
6
6
68
23
980
10,533
947
409
40994710,5339802368661378254168854
       Other Liabilities 
0
0
0
0
0
26
78
59
125
76
68
23
830
10,533
0
0
0010,53383023687612559782600000
> Total Stockholder Equity
238
203
1,569
858
862
1,644
1,907
2,274
3,035
3,824
5,618
4,429
7,990
57,609
47,433
40,376
40,37647,43357,6097,9904,4295,6183,8243,0352,2741,9071,6448628581,569203238
   Common Stock
1,019
1,143
1,569
2,055
2,260
2,910
3,200
4,343
5,655
6,842
8,482
8,482
9,331
12,904
12,904
12,904
12,90412,90412,9049,3318,4828,4826,8425,6554,3433,2002,9102,2602,0551,5691,1431,019
   Retained Earnings 
-1,221
-1,662
-2,310
-4,105
-4,694
-5,192
-5,219
-6,395
-6,947
-7,681
-7,970
-9,159
-7,464
22,259
12,083
5,216
5,21612,08322,259-7,464-9,159-7,970-7,681-6,947-6,395-5,219-5,192-4,694-4,105-2,310-1,662-1,221
   Capital Surplus 0000000000000000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
441
734
2,360
2,908
3,296
3,926
3,926
-8,339
4,459
4,663
5,106
5,106
0
0
0
-191
-1910005,1065,1064,6634,459-8,3393,9263,9263,2962,9082,360734441



6.3. Balance Sheets

Currency in EUR. All numbers in thousands.




6.4. Cash Flows

Currency in EUR. All numbers in thousands.




6.5. Income Statements

Currency in EUR. All numbers in thousands.